Get the Stockscreener App
4.42
9.05%
-0.44
After Hours:
3.44
-0.98
-22.17%
Design Therapeutics Inc stock is traded at $4.42, with a volume of 59,514.
It is down -9.05% in the last 24 hours and down -29.95% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
See More
Previous Close:
$4.86
Open:
$4.91
24h Volume:
59,514
Relative Volume:
0.35
Market Cap:
$250.26M
Revenue:
-
Net Income/Loss:
$-66.86M
P/E Ratio:
-3.6833
EPS:
-1.2
Net Cash Flow:
$-58.82M
1W Performance:
-11.07%
1M Performance:
-29.95%
6M Performance:
+4.99%
1Y Performance:
+89.70%
1-Day Range:
$4.40
$4.91
1-Week Range:
$4.40
$5.0899
52-Week Range:
$2.245
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
4.42 | 250.26M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
Design Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Update - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Position Increased by JPMorgan Chase & Co. - Defense World
Design Therapeutics: Not A Complete Washout Despite Setback - Seeking Alpha
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Breakthrough in Kidney Disease Treatment: Regulus Drug Shows Promising Results in Clinical Trial - StockTitan
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases - Yahoo Finance
Assenagon Asset Management S.A. Trims Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Ovid Therapeutics Inc. (NASDAQ:OVID) Position Cut by Assenagon Asset Management S.A. - Defense World
Assenagon Asset Management S.A. Buys New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Lululemon Athletica Inc. (NASDAQ:LULU) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Assenagon Asset Management S.A. Sells 782 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
Spinocerebellar Ataxias Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart
Long Term Trading Analysis for (DSGN) - Stock Traders Daily
3 Promising US Penny Stocks With Market Caps Under $900M - Simply Wall St
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Design Therapeutics, Inc. (NASDAQ:DSGN) Sees Significant Increase in Short Interest - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Up 8.1% in December - MarketBeat
Barclays PLC Purchases 24,602 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Sold by Jane Street Group LLC - Defense World
Design Therapeutics Updates Corporate Presentation for Investors - TipRanks
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE - BioSpace
Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases - Yahoo Finance
Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy - Business Wire
4D Molecular, FDA agree on phase 3 design for DME candidate - Seeking Alpha
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery - Yahoo Finance
Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics - Business Wire
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome - BioSpace
Barclays PLC Grows Position in Hooker Furnishings Co. (NASDAQ:HOFT) - Defense World
Geode Capital Management LLC Grows Stock Holdings in BARK, Inc. (NYSE:BARK) - Defense World
Geode Capital Management LLC Has $4.22 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Geode Capital Management LLC Buys 50,579 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
LPOXY Therapeutics Acquires Assets from Xeno Biosciences - Contract Pharma
Barclays PLC Has $520,000 Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics Inc (NASDAQ: DSGN) Could Fell Another -94.49% - Stocks Register
State Street Corp Has $3.72 Million Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
(DSGN) Trading Advice - Stock Traders Daily
Why Cemtrex Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket - Benzinga
PHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical Study - Business Wire
Toronto-Dominion Bank (NYSE:TD) Stock Rating Lowered by StockNews.com - Defense World
(DSGN) Investment Analysis - Stock Traders Daily
Design Therapeutics director Prasad Deepa sells shares worth $23,863 - Investing.com India
Design Therapeutics director Prasad Deepa sells shares worth $23,863 By Investing.com - Investing.com South Africa
Insider Selling: Design Therapeutics, Inc. (NASDAQ:DSGN) Director Sells 3,806 Shares of Stock - MarketBeat
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
The Manufacturers Life Insurance Company Purchases Shares of 13,221 Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Accelerating the Design of Candidate Drugs Using Amazon SageMaker with Nimbus Therapeutics - AWS Blog
Design Therapeutics' SWOT analysis: geneTAC stock faces early-stage hurdles - Investing.com
Fmr LLC Has $4.46 Million Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Neurological stocks rise and fall on clinical data; index down - BioWorld Online
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):